Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KalVista Pharmaceuticals (KALV – Research ...
JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data
JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions.
Business Insider1mon
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke as chief financial officer, effective ...
Seeking Alpha27d
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
Good afternoon, everyone. Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call. [Operator Instructions] Also, today's call is being recorded.